See more : Valentine Beauty, Inc. (VLBI) Income Statement Analysis – Financial Results
Complete financial analysis of Harrow Health, Inc. (HROW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Harrow Health, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Bank of America Corporation (BAC-PN) Income Statement Analysis – Financial Results
- Monarca Minerals Inc. (ORAGF) Income Statement Analysis – Financial Results
- Abeona Therapeutics Inc. (ABEO) Income Statement Analysis – Financial Results
- Blue Dart Express Limited (BLUEDART.BO) Income Statement Analysis – Financial Results
- Rimoni Industries Ltd. (RIMO.TA) Income Statement Analysis – Financial Results
Harrow Health, Inc. (HROW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.harrowinc.com
About Harrow Health, Inc.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.19M | 88.60M | 72.48M | 48.87M | 51.17M | 41.37M | 26.77M | 19.94M | 9.72M | 1.66M | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.64M | 25.38M | 18.21M | 14.46M | 16.75M | 16.52M | 13.51M | 9.83M | 5.21M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 90.55M | 63.21M | 54.26M | 34.41M | 34.42M | 24.85M | 13.27M | 10.11M | 4.51M | 567.41K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 69.55% | 71.35% | 74.87% | 70.41% | 67.26% | 60.07% | 49.56% | 50.70% | 46.42% | 34.18% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.88M | 3.05M | 11.08M | 2.41M | 2.08M | 825.00K | 413.00K | 739.00K | 332.00K | 236.66K | 1.62M | 1.30M | 111.55K | 194.59K | 2.97M | 1.99M | 1.83M | 150.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.96M | 17.57M | 12.50M | 8.09M | 5.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 430.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.06M | 7.38M | 6.50M | 2.39M | 85.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -423.79K |
| SG&A | 83.09M | 58.24M | 41.32M | 31.25M | 33.10M | 29.24M | 25.02M | 24.95M | 19.00M | 10.48M | 6.08M | 2.98M | 827.67K | 2.31M | 1.60M | 1.76M | 2.86M | 6.21K |
| Other Expenses | 0.00 | -15.93M | -19.49M | -3.80M | 630.00K | 103.00K | 0.00 | 1.54M | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -110.00K |
| Operating Expenses | 90.12M | 61.29M | 52.40M | 33.66M | 35.18M | 30.07M | 25.43M | 25.69M | 19.33M | 10.71M | 7.70M | 4.28M | 939.23K | 2.50M | 4.56M | 3.75M | 2.86M | 46.21K |
| Cost & Expenses | 129.76M | 86.68M | 70.61M | 48.12M | 51.93M | 46.59M | 38.94M | 35.52M | 24.54M | 11.81M | 7.70M | 4.28M | 939.23K | 2.50M | 4.56M | 3.75M | 2.86M | 46.21K |
| Interest Income | 0.00 | 7.24M | 5.44M | 2.24M | 0.00 | 0.00 | 0.00 | 10.00K | 13.00K | 32.45K | 43.76K | 15.41K | 0.00 | 512.00 | 10.44K | 67.01K | 48.44K | 0.00 |
| Interest Expense | 21.32M | 7.24M | 5.44M | 2.24M | 2.50M | 2.73M | 3.03M | 6.00M | 1.12M | 3.80K | 0.00 | 24.66K | 75.00K | 55.48K | 0.00 | 0.00 | 1.56M | -10.00K |
| Depreciation & Amortization | 12.34M | 3.67M | 2.40M | 2.74M | 2.66M | 1.84M | 1.77M | 1.41M | 610.00K | 85.35K | 5.66K | 2.94K | 338.00 | 1.06K | 1.06K | 704.00 | 201.25K | 0.00 |
| EBITDA | 9.72M | -3.20M | -10.14M | 3.49M | 1.44M | -2.73M | -10.40M | -14.06M | -14.21M | -10.06M | -7.64M | -5.36M | -878.60K | -2.47M | -4.55M | -4.12M | -2.75M | -46.21K |
| EBITDA Ratio | 7.47% | 2.17% | 2.91% | 2.27% | 4.22% | -7.21% | -55.59% | -59.13% | -146.27% | -604.06% | -76,374.65% | -4,160.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 431.00K | -1.75M | -284.00K | -1.63M | -503.00K | -5.22M | -12.16M | -15.88M | -14.82M | -10.15M | -7.69M | -4.18M | -939.23K | -2.50M | -4.56M | -3.75M | -2.86M | -46.21K |
| Operating Income Ratio | 0.33% | -1.97% | -0.39% | -3.34% | -0.98% | -12.61% | -45.43% | -79.64% | -152.55% | -611.16% | -76,868.79% | -4,178.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -24.37M | -15.93M | -19.49M | -3.80M | 386.00K | 19.84M | -757.00K | -3.32M | -1.08M | 28.65K | 43.76K | -1.20M | -14.71K | -28.67K | 10.44K | 375.00K | -1.43M | -533.79K |
| Income Before Tax | -23.94M | -14.01M | -17.87M | -3.42M | -125.00K | 14.63M | -12.92M | -19.20M | -15.90M | -10.12M | -7.64M | -5.38M | -953.94K | -2.53M | 0.00 | -3.37M | -2.77M | -580.00K |
| Income Before Tax Ratio | -18.39% | -15.81% | -24.66% | -6.99% | -0.24% | 35.35% | -48.26% | -96.27% | -163.64% | -609.43% | -76,431.24% | -5,383.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 470.00K | 75.00K | 133.00K | 4.00K | 2.47M | -19.45M | -935.00K | -111.00K | 1.08M | -28.65K | -43.76K | 1.20M | -60.29K | -26.30K | -10.44K | -817.01K | -228.27K | 10.00K |
| Net Income | -24.41M | -14.09M | -18.01M | -3.42M | -2.59M | 14.63M | -11.99M | -19.09M | -15.90M | -10.12M | -7.64M | -5.38M | -953.94K | -2.53M | -4.55M | -3.30M | -4.28M | -46.21K |
| Net Income Ratio | -18.75% | -15.90% | -24.85% | -7.00% | -5.07% | 35.35% | -44.76% | -95.71% | -163.64% | -609.43% | -76,431.24% | -5,383.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -0.51 | -0.67 | -0.13 | -0.10 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.20 | -2.40 | -6.41 | -11.67 | -8.92 | -19.37 | -0.25 |
| EPS Diluted | -0.75 | -0.51 | -0.67 | -0.13 | -0.10 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.20 | -2.40 | -6.41 | -11.67 | -8.92 | -19.37 | -0.25 |
| Weighted Avg Shares Out | 32.62M | 27.46M | 26.76M | 25.90M | 25.32M | 23.81M | 19.98M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.80K | 394.63K | 390.32K | 370.55K | 221.17K | 185.01K |
| Weighted Avg Shares Out (Dil) | 32.62M | 27.46M | 26.76M | 25.90M | 26.47M | 23.81M | 20.03M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.80K | 394.63K | 390.32K | 370.55K | 221.17K | 185.01K |
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
Harrow Health (HROW) Flat As Market Sinks: What You Should Know
Harrow Health: Mostly Good, Some Bad
Analysts Initiate Coverage: 5 Stocks for Higher Returns
Why Shares of Harrow Health Are Slumping Friday
Harrow Health, Inc. (HROW) Q1 2023 Earnings Call Transcript
Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
5 Stocks With Recent Price Strength That Still Have Upside
Here's Why Momentum in Harrow (HROW) Should Keep going
Source: https://incomestatements.info
Category: Stock Reports